Latest news

• Moderna announces trial results for new COVID-19 booster vaccine candidate

  Moderna has shared new clinical data evaluating its COVID-19 booster vaccine candidate, mRNA-1273.214 – containing mRNA-1273 (Spikevax) – and a vaccine candidate targeting the Omicron sub-variant. ... an innovation in the fight against COVID-19.

• AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

  AstraZeneca has received approval from the European Medicine Agency (EMA) for its COVID-19 vaccine, Vaxzevria, to be used as a third-dose booster to protect adults against the virus. ... Mene Pangalos, executive vice president, BioPharmaceuticals R&D,

• FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

  Eligible adults can have had any authorised COVID-19 vaccine as their first booster. ... A second booster dose has also authorised for those aged 12 years and older who are immunocompromised, and have had a first booster dose of any authorised COVID-19

• FDA to review requirements for future booster shots for COVID-19

  The meeting is to discuss requirements for future COVID-19 vaccine boosters and the process for selecting specific strains of coronavirus for COVID-19 vaccines to address current and new, emerging ... The committee will review the need to update the

• Pfizer/BioNTech receives expanded authorisation from the FDA for its COVID-19 booster

  The booster dose of the companies’ COVID-19 vaccine is now authorised to include individuals aged 12 years and older. ... The US Food and Drug Administration (FDA) has granted Pfizer-BioNTech an expanded emergency use authorisation (EUA) for the